Tower Research Capital (TRC)’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Tower Research Capital (TRC)’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,637	Closed	-$2K	–	4657
2018 Q2	$2K	Buy	+1,637	New	+$2.51K	﹤0.01%	3445
2017 Q2	–	Sell	-3,358	Closed	-$11K	–	4041
2017 Q1	$11K	Buy	3,358 +2,758	+460%	+$10.7K	﹤0.01%	1743
2016 Q4	$3K	Buy	+600	New	+$2.48K	﹤0.01%	3368
2016 Q2	–	Sell	-69	Closed	–	–	5573
2016 Q1	$0	Sell	69 -1,920	-97%	-$7.43K	﹤0.01%	5783
2015 Q4	$8K	Sell	1,989 -1,705	-46%	-$7.86K	﹤0.01%	2525
2015 Q3	$14K	Sell	3,694 -10,818	-75%	-$49.7K	﹤0.01%	2076
2015 Q2	$67K	Buy	+14,512	New	+$139K	0.01%	1149

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tower Research Capital (TRC)'s AST Position: Q3 2018 in Review

Tower Research Capital (TRC) sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2018, closing a stake of 1,637 shares — an estimated $2K sold.

Tower Research Capital (TRC) first reported a position in AST in Q2 2015 and held it in 7 quarters. The position peaked at $67K in Q2 2015. 54 funds tracked by Wall St. Rank hold AST as of Q3 2018.

Tower Research Capital (TRC) reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2018 after selling out during the quarter.
Tower Research Capital (TRC) sold 1,637 Asterias Biotherapeutics Inc. Series A shares in Q3 2018, an estimated $2K.
Tower Research Capital (TRC) first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 7 quarters.
Tower Research Capital (TRC)'s Asterias Biotherapeutics Inc. Series A position peaked at $67K in Q2 2015.
54 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2018.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2018, filed 13 Nov 2018.